Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 13/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29631908 | 0.87 | NR1H2 (0.39) | CCR2NR1H2NR1H3ACLY | |
| SCHEMBL19013556 | 0.87 | NR1H2 (0.39) | CCR2NR1H2NR1H3ACLY | |
| SCHEMBL24112569 | 0.82 | ACLY (0.34) | NR1H2NR1H3ACLYMCL1 | |
| SCHEMBL24020795 | 0.82 | CCR9 (0.36) | CCR2NR1H2NR1H3ACLY | |
| SCHEMBL30310674 | 0.82 | ACLY (0.34) | NR1H2NR1H3ACLYMCL1 | |
| SCHEMBL22462567 | 0.82 | CCR2 (0.37) | CCR2NR1H2NR1H3ACLY | |
| SCHEMBL20846321 | 0.81 | NR1H2 (0.40) | CCR2NR1H2NR1H3ACLYCA12 | |
| SCHEMBL29631833 | 0.81 | NR1H2 (0.42) | CCR2NR1H2NR1H3ACLYCA12 | |
| SCHEMBL4242068 | 0.81 | NR1H2 (0.40) | CCR2NR1H2NR1H3ACLYCA12 | |
| SCHEMBL24554901 | 0.80 | NR1H2 (0.38) | CCR2NR1H2NR1H3ACLYCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013333-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3013333-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2019-03-27 | — | — | EP | disclosed |
| US-9549921-B2 | Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C | MERCK SHARP & DOHME CORP. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160143895-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | US | disclosed |
| EP-3013333-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | Merck Sharp & Dohme Corp. (US) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014205592-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME CORP. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014209729-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME CORP. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014209729-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME CORP. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014205592-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME CORP. (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160143895-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | HCCS, HAVCR2, CPS1 | CCR2 1637/4885NR1H2 353/4885NR1H3 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.